BlueCrest Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

BlueCrest Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,364	Closed	-$345K	–	136
2024 Q1	$345K	Sell	6,364 -52,701	-89%	-$2.68M	0.02%	183
2023 Q4	$3.03M	Buy	59,065 +40,501	+218%	+$2.13M	0.12%	130
2023 Q3	$1.08M	Buy	+18,564	New	+$1.14M	0.05%	175
2019 Q4	–	Sell	-5,766	Closed	-$292K	–	408
2019 Q3	$292K	Buy	+5,766	New	+$271K	0.02%	371
2019 Q1	–	Sell	-13,153	Closed	-$655K	–	1182
2018 Q4	$684K	Sell	13,153 -1,616	-11%	-$86.8K	0.04%	282
2018 Q3	$917K	Buy	14,769 +1,285	+10%	+$76.3K	0.02%	478
2018 Q2	$746K	Buy	+13,484	New	+$728K	0.02%	641
2017 Q3	–	Sell	-10,931	Closed	-$609K	–	857
2017 Q2	$609K	Buy	+10,931	New	+$595K	0.02%	551
2017 Q1	–	Sell	-28,500	Closed	-$1.67M	–	749
2016 Q4	$1.67M	Buy	+28,500	New	+$1.56M	0.09%	283
2016 Q1	–	Sell	-4,613	Closed	-$317K	–	792
2015 Q4	$317K	Buy	+4,613	New	+$305K	0.01%	723

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlueCrest Capital Management's BMY Position: Q2 2024 in Review

BlueCrest Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 6,364 shares — an estimated $345K sold.

BlueCrest Capital Management first reported a position in BMY in Q4 2015 and held it in 10 quarters. The position peaked at $3.03M in Q4 2023. 2,154 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

BlueCrest Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
BlueCrest Capital Management sold 6,364 Bristol-Myers Squibb shares in Q2 2024, an estimated $345K.
BlueCrest Capital Management first reported a position in Bristol-Myers Squibb in Q4 2015 and held it in 10 quarters.
BlueCrest Capital Management's Bristol-Myers Squibb position peaked at $3.03M in Q4 2023.
2,154 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on BlueCrest Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.